Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study

Clinical Trials

Volumn 4, Issue 4, 2007, Pages 357-367

  Lok, Charmaine E ^a   Allon, Michael ^b   Donnelly, Sandra ^c   Dorval, Marc ^d   Hemmelgarn, Brenda ^e   Moist, Louise ^f   Oliver, Matthew J ^g   Tonelli, Marcello ^h   Stanley, Kenneth ⁱ  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Dr Georges L Dumont Regional Hospital   (Canada)

^e FOOTHILLS HOSPITAL   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; PLACEBO;

ARTICLE; BLOOD VESSEL GRAFT; BLOOD VESSEL OCCLUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GRAFT FAILURE; GRAFT PATENCY; GRAFT SURVIVAL; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; VASCULAR ACCESS;

CONSTRICTION, PATHOLOGIC; ENDPOINT DETERMINATION; FISH OILS; GRAFT OCCLUSION, VASCULAR; HUMANS; REGISTRIES; RENAL DIALYSIS; RESEARCH DESIGN; SAMPLE SIZE; THROMBOEMBOLISM; TRANSPLANTS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 35348819450     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507081218     Document Type: Article

References (81)

1. U.S. renal data system, USRDS 2005. Annual data report: Atlas of endstage renal disease in the United States. In: Incidence and Prevalence; Patient Characteristics. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Betheseda, MD, 2005.
2. Treatment of end-stage organ failure in Canada. Canadian Institute for Health Information, Ottawa, 2005.
3. Lee H, Manns B, Taub K et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002; 40: 611-22.
4. Churchill DN, Taylor DW, Cook RJ et al. Canadian hemodialysis morbidity study. Am J Kidney Dis 1992; 19: 214-34.
5. Woods JD, Turenne MN, Strawderman RL et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 1997; 30: 50-57.
6. Lok CE, Oliver MJ, Rothwell DM, Hux JE. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant 2004; 19: 3098-103.
7. CORR Preliminary Report. In.: www.cihi.ca; 2002.
8. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62: 1109-24.
9. Miller PE, Tolwani A, Luscy CP et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int 1999; 56: 275-80.
10. Schwab SJ, Harrington JT, Singh A et al. Vascular access for hemodialysis. Kidney Int 1999; 55: 2078-90.
11. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000; 36: 68-74.
12. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 2006; 17: 1112-27.
13. Kobayashi K, Maeda K, Koshikawa S et al. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis - a multicenter collaborative double blind study. Thromb Res 1980; 20: 255-61.
14. Harvey R, Bredenberg CE, Couper L, Himmelfarb J. Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Vasc Surg 1997; 25: 689-95.
15. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477-83.
16. Diskin CJ, Stokes TJ Jr., Pennell AT. Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 1993; 64: 1-26.
17. Dixon BS, Beck GJ, Dember LM et al. Design of the dialysis access consortium (DAC) aggrenox prevention of access stenosis trial. Clin Trials 2005; 2: 400-12.
18. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997; 11: 485-91.
19. Nordoy A, Marchioli R, Arnesen H, Videbaek J. n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids 2001; 36: S127-29.
20. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991; 54: 438-63.
21. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165: 725-30.
22. Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol 2006; 1: 182-92.
23. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 2002; 13: 184-90.
24. Friedman LM, Furberg CD, DeMets DL. Sample size. Fundamentals of clinical trials. (Third ed.) Springer, New York, 94-129, 1998.
25. Mehta CR, Patel NR. A network algorithm for the exact treatment of Fisher's exact test in RxC contingency tables. J Amer Stat Assn 1982; 78: 427-34.
26. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley, New York, 1980.
27. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-33.
28. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun 1988; 156: 960-63.
29. Holub BJ, Skeaff CM. Nutritional regulation of cellular phosphatidylinositol. Methods Enzymol 1987; 141: 234-44.
30. Stark KD, Park EJ, Maines VA, Holub BJ. Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial. Am J Clin Nutr 2000; 72: 389-94.
31. Jindal K, Ethier JH, Linsay RM. Clinical practise guidelines for vascular access. J Am Soc Nephrol 1999; 10: 287-321.
32. Foundation NK: NKF-K/DOQI Clinical practice guidelines for vascular access: Update 2000. Am J Kidney Dis 2001; 37: S137-181.
33. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-69.
34. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80: 1726-36.
35. Sottiurai VS, Yao JS, Flinn WR, Batson RC. Intimal hyperplasia and neointima: An ultrastructural analysis of thrombosed grafts in humans. Surgery 1983; 93: 809-17.
36. Sukhatme VP. Vascular access stenosis: prospects for prevention and therapy. Kidney Int 1996; 49: 1161-74.
37. Hehrlein C. How do AV fistulae lose function? The roles of haemodynamics, vascular remodelling, and intimal hyperplasia. Nephrol Dial Transplant 1995; 10: 1287-90.
38. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-23.
39. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr., Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994; 14: 1829-36.
40. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 1978; 2: 117-19.
41. Rylance PB, Gordge MP, Saynor R, Parsons V, Weston MJ. Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients. Nephron 1986; 43: 196-202.
42. Van Acker BA, Bilo HJB, Popp-Snijders C, Van Bronswijk H, Oe PL, Donker AJ. The effect of fish oil on lipid profile and viscosity of erythrocyte suspensions in CAPD patients. Nehprol Dial Transplant 1987; 2: 557-61.
43. Ombrellaro MP, Stevens SL, Schaeffer DO et al. The role of platelet-derived growth factor in intraluminal stented graft healing. J Am Coll Surg 1997; 184: 49-57.
44. Faries PL, Marin ML, Veith FJ et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. J Vasc Surg 1996; 24: 463-71.
45. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 2001; 37: 970-80.
46. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-37.
47. Ruef J, Peter K, Nordt TK, Runge MS, Kubler W, Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost 1999; 82: 32-37.
48. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
49. Aviram M. LDL-platelet inteaction under oxidative stress induces macrophage foam cell formation. Thromb Haemost 1997; 74: 560-64.
50. Fukai T, Folz RJ, Landmesser U, Harrison DG. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res 2002; 55: 239-49.
51. Berk BC. Redox signals that regulate the vascular response to injury. Thromb Haemost 1999; 82: 810-17.
52. Huynh TT, Davies MG, Trovato MJ, Barber L, Safi HJ, Hagen PO. Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreases intimai hyperplasia in experimental vein grafts. J Surg Res 1999; 84: 223-32.
53. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999; 10: 2177-84.
54. Mori TA, Puddey IB, Burke V et al. Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox Rep 2000; 5: 45-46.
55. Vericel E, Calzada C, Chapuy P, Lagarde M. The influence of low intake of n-3 fatty acids on platelets in elderly people. Atherosclerosis 1999; 147: 187-92.
56. Terano T, Shiina T, Tamura Y. Eicosapentaenoic acid suppressed the proliferation of vascular smooth muscle cells through modulation of various steps of growth signals. Lipids 1996; 31: S301-304.
57. Nakayama M, Fukuda N, Watanabe Y et al. Low dose of eicosapentaenoic acid inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats through suppression of transforming growth factor-beta. J Hypertens 1999; 17: 1421-30.
58. Fox PL, DiCorleto PE. Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science 1988; 241: 453-56.
59. Libby P, Warner SJ, Salomon RN, Birinyi LK. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med 1988; 318: 1493-98.
60. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 2000; 36: 851-55.
61. DeCaterina R, Giannessi D, Mazzone A et al. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 1990; 82: 428-38.
62. Shimokawa H, Lam JY, Chesebro JH, Bowie EJ, Vanhoutte PM. Effects of dietary supplementation with cod-liver oil on endothelium-dependent responses in porcine coronary arteries. Circulation 1987; 76: 898-905.
63. Boulanger C, Schini VB, Hendrickson H, Vanhoutte PM. Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol 1990; 99: 176-80.
64. Harris WS, Rambjor GS, Windsor SL, Diederich D. n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr 1997; 65: 459-64.
65. Eritstand J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77: 31-36.
66. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol 1992; 2: 1634-39.
67. Eritsland J. Safety considerations of polyunsaturated fatty acids. Am J Clin Nutr 2000; 71(Suppl 1): 197-201.
68. Efrati S, Zaidenstein R, Dishy V et al. ACE inhibitors and survival of hemodialysis patients. American Journal of Kidney Diseases 2002; 40: 1023-29.
69. Tonnessen BH, Money SR. Embracing the fistula first national vascular access improvement initiative. J Vasc Surg 2005; 42: 585-86.
70. Canadian Organ Replacement Register, 1991 Annual Report. Hospital Medical Records Institute, Don Mills, Ontaro, 1991.
71. Moist LM, Churchill DN, House AA et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 2003; 14: 2645-53.
72. Ram SJ, Work J, Caldito GC, Eason JM, Pervez A, Paulson WD. A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts. Kidney Int 2003; 64: 272-80.
73. Dember LM, Holmberg EF, Kaufman JS. Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis. Kidney Int 2004; 66: 390-98.
74. Robbin ML, Oser RF, Lee JY, Heudebert GR, Mennemeyer ST, Allon M. Randomized comparison of ultrasound surveillance and clinical monitoring on arteriovenous graft outcomes. Kidney Int 2006; 69: 730-35.
75. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-19.
76. van Jaarsveld BC, Krijnen P, Pieterman H et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 2000; 342: 1007-14.
77. 2003 annual report: ESRD clinical performance measures project. Am J Kidney Dis 2004; 44: S1-92.
78. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney International 2001; 60: 1443-51.
79. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J. For the CHOICE study: type of vascular access and survival among incident hemodialysis patients: the choices for healthy outcomes in caring for ESRD (CHOICE) study. J Am Soc Nephrol 2005; 16: 1449-55.
80. Allon M, Daugirdas J, Depner TA et al. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis 2006; 47: 469-77.
81. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United States dialysis population, 1991 to 1999. Journal of the American Society of Nephrology 2004; 15: 1038-45.